|
CN112174886A
|
|
Preparation method of Levatinib mesylate crystal form X
|
|
CN112190583A
|
|
Levatinib pharmaceutical composition and preparation method thereof
|
|
WO2019228485A1
|
|
New crystal form of lenvatinib mesylate and preparation method therefor
|
|
CN109761858A
|
|
A kind of refining methd of gabexate mesilate
|
|
CN111406071A
|
|
PASylated VEGFR/PDGFR fusion proteins and their use in therapy
|
|
WO2019096226A1
|
|
Pasylated vegfr/pdgfr fusion proteins and their use in therapy
|
|
CN108623541A
|
|
A kind of preparation method of hexichol pyrazine compound
|
|
CN108774183A
|
|
A kind of preparation method of ethylene glycol compounds
|
|
CN108863955A
|
|
Diphenyl pyrazine class compound or its pharmaceutically acceptable salt, isomers and its preparation method and application
|
|
CN108822149A
|
|
A kind of fumaric acid tenofovir Chinese mugwort draws the preparation method of phenol amine key intermediate
|
|
CN108373423A
|
|
Preparation method of the one planting sand library than bent Valsartan compound and/or eutectic key intermediate sand library than bent calcium
|
|
CN107573375A
|
|
A kind of Memantine derivative and preparation method thereof
|
|
WO2018019296A1
|
|
Aminopyrazine compound, salt, or isomer, preparation method therefor, and application thereof
|
|
CN105616362A
|
|
Parecoxib sodium pharmaceutical composition for injection and preparation method thereof
|
|
CN105663131A
|
|
Repaglinide and metformin hydrochloride tablet pharmaceutical composition and preparation method thereof
|
|
CN105669581A
|
|
Angiotensin receptor antagonist/neutral endopeptidase inhibitor composite
|
|
CN106543141A
|
|
Uracil derivative
|
|
CN106008507A
|
|
Xanthine derivative
|
